These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 25459191)

  • 1. Clinical usefulness of therapeutic drug monitoring of voriconazole in a university hospital.
    Cabral-Galeano E; Ruiz-Camps I; Len-Abad O; Pou-Clavé L; Sordé-Masip R; Meije-Castillo Y; Blanco-Grau A; Barba-Suñol P; Monforte-Torres V; Román-Broto A; Pahissa-Berga A; Gavaldà-Santapau J
    Enferm Infecc Microbiol Clin; 2015 May; 33(5):298-302. PubMed ID: 25459191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Voriconazole therapeutic drug monitoring: results of a prematurely discontinued randomized multicenter trial.
    Neofytos D; Ostrander D; Shoham S; Laverdiere M; Hiemenz J; Nguyen H; Clarke W; Brass L; Lu N; Marr KA
    Transpl Infect Dis; 2015 Dec; 17(6):831-7. PubMed ID: 26346408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients.
    Berge M; Guillemain R; Boussaud V; Pham MH; Chevalier P; Batisse A; Amrein C; Dannaoui E; Loriot MA; Lillo-Le Louet A; Billaud EM
    Transpl Infect Dis; 2009 Jun; 11(3):211-9. PubMed ID: 19302272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing Azole Plasma Trough Levels in Lung Transplant Recipients: Percentage of Therapeutic Levels and Intrapatient Variability.
    Stelzer D; Weber A; Ihle F; Matthes S; Ceelen F; Zimmermann G; Kneidinger N; Schramm R; Winter H; Zoller M; Vogeser M; Behr J; Neurohr C
    Ther Drug Monit; 2017 Apr; 39(2):93-101. PubMed ID: 28282366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of plasma unbound fraction of voriconazole in patients treated with a prophylactic or a curative treatment.
    Florent A; Gandia P; Seraissol P; Chatelut E; Houin G
    Ther Drug Monit; 2014 Dec; 36(6):752-8. PubMed ID: 24819971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic drug monitoring of voriconazole helps to decrease the percentage of patients with off-target trough serum levels.
    Guinea J; Escribano P; Marcos-Zambrano LJ; Peláez T; Kestler M; Muñoz P; Vena A; López-Fabal F; Bouza E
    Med Mycol; 2016 May; 54(4):353-60. PubMed ID: 26739190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic drug monitoring in the treatment of invasive aspergillosis with voriconazole in cancer patients--an evidence-based approach.
    Karthaus M; Lehrnbecher T; Lipp HP; Kluge S; Buchheidt D
    Ann Hematol; 2015 Apr; 94(4):547-56. PubMed ID: 25697592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Voriconazole and posaconazole therapeutic drug monitoring: a retrospective study.
    Yi WM; Schoeppler KE; Jaeger J; Mueller SW; MacLaren R; Fish DN; Kiser TH
    Ann Clin Microbiol Antimicrob; 2017 Sep; 16(1):60. PubMed ID: 28893246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial.
    Park WB; Kim NH; Kim KH; Lee SH; Nam WS; Yoon SH; Song KH; Choe PG; Kim NJ; Jang IJ; Oh MD; Yu KS
    Clin Infect Dis; 2012 Oct; 55(8):1080-7. PubMed ID: 22761409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different effects of lansoprazole and rabeprazole on the plasma voriconazole trough levels in allogeneic hematopoietic cell transplant recipients.
    Yasu T; Konuma T; Kato S; Kurokawa Y; Takahashi S; Tojo A
    Ann Hematol; 2016 Oct; 95(11):1845-51. PubMed ID: 27535751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes of lung-transplant recipients treated by voriconazole and caspofungin combination in aspergillosis.
    Thomas A; Korb V; Guillemain R; Caruba T; Boussaud V; Billaud E; Prognon P; Begué D; Sabatier B
    J Clin Pharm Ther; 2010 Feb; 35(1):49-53. PubMed ID: 20175811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Voriconazole therapeutic drug monitoring among lung transplant recipients receiving targeted therapy for invasive aspergillosis.
    Butler-Laporte G; Langevin MC; Lemieux C; Poirier C; Ferraro P; Théorêt Y; Luong ML
    Clin Transplant; 2022 Aug; 36(8):e14709. PubMed ID: 35575963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Voriconazole concentration is inversely correlated with corticosteroid usage in immunocompromised patients.
    Imataki O; Yamaguchi K; Uemura M; Fukuoka N
    Transpl Infect Dis; 2018 Aug; 20(4):e12886. PubMed ID: 29570914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Importance of voriconazole therapeutic drug monitoring in pediatric cancer patients with invasive aspergillosis.
    Choi SH; Lee SY; Hwang JY; Lee SH; Yoo KH; Sung KW; Koo HH; Kim YJ
    Pediatr Blood Cancer; 2013 Jan; 60(1):82-7. PubMed ID: 22887791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic drug monitoring-guided treatment versus standard dosing of voriconazole for invasive aspergillosis in haematological patients: a multicentre, prospective, cluster randomised, crossover clinical trial.
    Veringa A; Brüggemann RJ; Span LFR; Biemond BJ; de Boer MGJ; van den Heuvel ER; Klein SK; Kraemer D; Minnema MC; Prakken NHJ; Rijnders BJA; Swen JJ; Verweij PE; Wondergem MJ; Ypma PF; Blijlevens N; Kosterink JGW; van der Werf TS; Alffenaar JC;
    Int J Antimicrob Agents; 2023 Feb; 61(2):106711. PubMed ID: 36642232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience.
    Racil Z; Winterova J; Kouba M; Zak P; Malaskova L; Buresova L; Toskova M; Lengerova M; Kocmanova I; Weinbergerova B; Timilsina S; Rolencova M; Cetkovsky P; Mayer J
    Mycoses; 2012 Nov; 55(6):483-92. PubMed ID: 22429709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic drug monitoring and safety of intravenous voriconazole formulated with sulfobutylether β-cyclodextrin in haematological patients with renal impairment.
    Kim SH; Kwon JC; Park C; Han S; Yim DS; Choi JK; Cho SY; Lee HJ; Park SH; Choi SM; Choi JH; Yoo JH; Lee DG; Lee JW
    Mycoses; 2016 Oct; 59(10):644-51. PubMed ID: 27324913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Voriconazole concentrations and outcome of invasive fungal infections.
    Miyakis S; van Hal SJ; Ray J; Marriott D
    Clin Microbiol Infect; 2010 Jul; 16(7):927-33. PubMed ID: 19845698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Voriconazole dosing and therapeutic drug monitoring in children: experience from a paediatric tertiary care centre.
    Boast A; Curtis N; Cranswick N; Gwee A
    J Antimicrob Chemother; 2016 Jul; 71(7):2031-6. PubMed ID: 27009030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinician ordering practices for voriconazole therapeutic drug monitoring: experiences of a referral laboratory.
    Miyakis S; van Hal SJ; Solvag CJ; Ray J; Marriott D
    Ther Drug Monit; 2010 Oct; 32(5):661-4. PubMed ID: 20720520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.